Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

completed133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

NCT05183958
completed

Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study

NCT04546243
unknownnot_applicable

Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial)

NCT03583723

Clinical Trials (3)

Showing 3 of 3 trials
NCT05183958Phase 2

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Unknown
NCT04546243

Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study

Completed
NCT03583723Not Applicable

Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial)

Unknown

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3